Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.35 |
| ▸ | FABP3 | P05413 | 2/20 | 0.34 |
| ▸ | FABP4 | P15090 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | CSF1R | P07333 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2931594 | 0.86 | RXFP1 (0.44) | MAPTMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL2925046 | 0.85 | MAPT (0.39) | MAPTMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL1115893 | 0.84 | MAPT (0.42) | MAPTMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL2932570 | 0.82 | MAPT (0.42) | MAPTMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL13989934 | 0.80 | MEN1 (0.45) | MAPTMEN1KMT2AALDH1A1PBRM1 | |
| SCHEMBL2931556 | 0.79 | MAPT (0.39) | MAPTMEN1KMT2AFABP3FABP4 | |
| SCHEMBL1116247 | 0.79 | MAPT (0.44) | MAPTMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL12856603 | 0.78 | MAPT (0.46) | MAPTMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL2931417 | 0.78 | MAPT (0.39) | MAPTMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL2927954 | 0.76 | MAPT (0.39) | MAPTKMT2ASMN1; SMN2ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910314-B1 | BENZIMIDAZOLE DERIVATIVES FOR TREATMENT OF INFLAMMATORY DISEASES | NOVARTIS AG (CH) | 2010-09-15 | — | — | EP | disclosed |
| EP-1910314-B1 | BENZIMIDAZOLE DERIVATIVES FOR TREATMENT OF INFLAMMATORY DISEASES | NOVARTIS AG (CH) | 2010-09-15 | — | — | EP | disclosed |
| US-20080306064-A1 | Benzimidazole Derivatives | BROWN LYNDON NIGEL | 2008-12-11 | — | — | US | disclosed |
| US-20080306064-A1 | Benzimidazole Derivatives | BROWN LYNDON NIGEL | 2008-12-11 | — | — | US | disclosed |
| US-20080306064-A1 | Benzimidazole Derivatives | BROWN LYNDON NIGEL | 2008-12-11 | — | — | US | disclosed |
| EP-1910314-A1 | BENZIMIDAZOLE DERIVATIVES FOR TREATMENT OF INFLAMMATORY DISEASES | Novartis AG (CH) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007009774-A1 | BENZIMIDAZOLE DERIVATIVES FOR TREATMENT OF INFLAMMATORY DISEASES | NOVARTIS AG (CH) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007009774-A1 | BENZIMIDAZOLE DERIVATIVES FOR TREATMENT OF INFLAMMATORY DISEASES | NOVARTIS AG (CH) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306064-A1 | Benzimidazole Derivatives | PPARG, PPARD, BRD4 | MAPT 2716/4885MEN1 4765/4885KMT2A 3456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.